I N T E R N A T I O N A L S O C I E T Y O F

P H A R M A C O V I G I L A N C E

P h a r m a c o v i g i l a n c e -C u r r e n t a n d F u t u r e C h a l l e n g e s

4 T H A N N U A L M E E T I N G

(ii)

6 T H - 8 T H O C T O B E R , D U B L I N , I R E L A N D

V E N U E

The Conrad Hotel Dublin,

Earlsfort Terrace,

Dublin 2,

Ireland

Tel: +353 1 602 8900

Fax: +353 1 676 5424Email: dublininfo@conradhotels.comor www.conradmeetings.com

The Conrad Dublin is located off St. Stephen's Green in the downtown commercial district, a few

minutes walk from the main shopping and cultural centres and is directly opposite the National

Concert Hall. The hotel is only minutes from the fashionable shopping area of Grafton Street

P L E A S E N O T E

Smoking is not permitted in any public areas at the meeting venue,

or in any public place in Ireland.

(iii)

C O N T E N T S

Organisers .....................................3

Welcome Address...........................4

At the Venue..................................5

Scientific Programme .....................7

Posterlist ........................................14

Social Programme ..........................19

General Information ......................20

1

P R E C E D I N G C O N F E R E N C E S

In 2000 the European Society of Pharmacovigilance changed its name to theInternational Society of Pharmacovigilance:

1993 Geneva, Switzerland1994 Rouen, France1995 Cambridge, England1996 Lisbon, Portugal1997 Berlin, Germany1998 Budapest, Hungary1999 Ankara, Turkey2000 Verona, Italy2001 Carthage-Tunis, Tunisia2002 Amsterdam, The Netherlands2003 Marrakesh, Morocco2004 Dublin, Ireland

I S O P E X E C U T I V E C O M M I T T E E

Giampaolo Velo, President ItalyChalbi Belkahia, Vice-President TunisiaNicholas Moore, Secretary General FranceBrian Edwards, Treasurer United KingdomJürgen Beckmann, GermanyAna Maria Corrêa-Nunes, PortugalIain Cockburn United KingdomRalph Edwards (Past President) SwedenKees van Grootheest The NetherlandsElisabeth Loupi FrancePaula Marquez Padorno SpainRonald Meyboom The NetherlandsMichel Ollagnier FranceRachida Soulaymani MoroccoRènè-Jean Royer (Honarary President) France

The aim of the International Society of Pharmacovigilance (ISoP) is to provide an international

forum for all those with an interest in the clinical and scientific aspects of drug safety- and not

only full-time pharmacovigilance professionals. Our society consists of members from industry,

governmental agencies, research and academic bodies.

For information about membership, please contact:International Society of Pharmacovigilance

PO Box 32 974,London SW19 8YG,

Phone/Fax: +44(0)20 82861888Email: administration@isoponline.org

Website: www.isoponline.org

2

O R G A N I Z E R S

ORGANIZING COMMITTEE (LOCAL)

Joan Gilvarry

Niamh Arthur

Deirdre McCarthy

Wendy Donoghue

SCIENTIFIC COMMITTEE

Jürgen Beckmann, Chairman

Niamh Arthur

Iain Cockburn

Joan Gilvarry

Paula Marquez Padorno

Thierry Trenque

POSTER PRIZE JURY

Sandeep Agarwal

Ana Maria Corrêa-Nunes

Kees van Grootheest

3

W E L C O M E A D D R E S S

Dear Colleagues,

It is with great pleasure that we welcome you to Ireland’s capital city, Dublin, to attend

the 4th Annual Meeting of the International Society of Pharmacovigilance.

We hope that you will enjoy your stay in this lovely, historic and vibrant city. The

venue for our meeting is centrally located near the heart of Georgian Dublin, while also

easily accessible to a beautiful nearby park and within easy reach of all the

recommended meeting hotels.

The Scientific Committee has taken account of feedback from the last meeting of ISoP

in Marrakesh, so we hope that the proposed scientific programme will be of great

interest to you.

The overall theme of the conference ‘Pharmacovigilance - Current and Future

Challenges’ has been chosen in order to cover a large range of topical and evolving

important pharmacovigilance issues. We hope you will find the conference stimulating,

educational and beneficial, as well as an opportunity to make new friends and renew

old friendships.

On behalf of the Organizing Committee, I look forward to meeting you in Dublin to

celebrate this important event and to enjoy our historic and charming city.

Niamh ArthurPresident of the Local Organizing Committee

4

A T T H E V E N U E

P R A C T I C A L I N F O R M A T I O N

Registration Desk

• The registration desk will be open every day from 8.00 a.m. until the end of all

scientific sessions and will provide:

• Conference material for registered participants

• On-site Conference registration

• Message service to and from participants

• Tickets for Conference Dinner

Bags and Badges:

• You will receive your conference badge when you register. Please wear it at

all times to identify you as a conference participant and for your coffee and

lunch breaks.

• You will also receive a delegates’ bag containing the conference brochure

and other useful information.

Internet access/e-mails:

• Access to the Internet will be available in the pre-function area during

meeting hours

Speakers’ room:

• Staff will be available in the Speakers’ Room (1st floor, Boardroom 1) for the

duration of the conference to assist with presentations etc.

• Speakers are requested to provide their presentation on diskette or CD Rom as early

as possible on the day of their presentation.

• The staff in the Speakers’ Room will also be happy to provide you with information

and leaflets on transportation, sightseeing etc. around Dublin.

Taxis:

• A taxi rank is situated just outside the hotel.

Please note that smoking is not permitted at any venue (meeting/social/buses/taxis etc.) in Ireland

5

M E E T I N G T I M E T A B L E

W E D N E S D A Y , O C T O B E R 6 , 2 0 0 4

12.00: Arrival and Registration

13.00-14.00: Lunch

14.00-17.15: Joint session with the 27th WHO National Centres Meeting

18.30-20.30: Welcome Reception, Chester Beatty Library, Dublin Castle

T H U R S D A Y , O C T O B E R 7 , 2 0 0 4

08.00-09.00: Registration

09.00-09.20: Opening Ceremony

09.20-11.00: Parallel Sessions 1 and A

11.20-13.00: Parallel Sessions 2 and B (including coffee break)

13.00-14.20: Lunch and poster session

14.20-16.00: Parallel Sessions 3 and C (including coffee break)

16.20-18.00: Parallel Sessions 4 and D

19.00-22.30: Conference dinner (Old Jameson Distillery, Smithfield, Dublin)

F R I D A Y , O C T O B E R 8 , 2 0 0 4

09.00-10.40: Parallel Sessions 5 and E

11.00-12.40: Parallel Sessions 6 and F (including coffee break)

12.40-14.00: Lunch and poster session

14.00-14.50: Overview of key meeting issues and awarding of poster prizes

14.50-15.40 Keynote Address

15.40-16.30: General Assembly, poster prize

16.30-17.00: Closing Session; Invitation to ISoP 2005

6

S C I E N T I F I C P R O G R A M M E

7

M E E T I N G R O O M L O C A T I O N

8

PlenaryHall

PlenaryHall

PlenaryHall

Ground FloorCONRAD BALLROOM

Liffey Dodder Dargle

W E D N E S D A Y , 6 T H O C T O B E R

P L E N A R Y H A L L

9

12.40 - 14.00 LUNCH

14.00 JO I N T SE S S I O N W I T H T H E WHO AN N U A L ME E T I N G O F

NAT I O N A L CE N T R E S

Dr Joan Gi lvarry , I r i sh Medic ines Board

Prof Vladimir Lepakhin, WHO Geneva

Prof Giampaolo Velo, Pres ident of ISoP

14.00-14.10 CH A I R P E R S O N’S IN T R O D U C T O RY RE M A R K S

14.10-15.00 1. KE Y N O T E A D D R E S S

‘The Mountain Peaks and Pitfal ls of being Spontaneous’

Professor S tephen Evans

15.00-15.15 CO F F E E BR E A K

15:15-15:30

15:30-16:15

16:15-16:45

16:45-17:00

17:00 -17:15

18:30 –20:30

20:00-22:30

Review of the preceding 27th Annual Meeting of National Centres

participating in the WHO International Drug Monitoring Programme

Dr Mary Couper, WHO Geneva

Survei l lance of ADRs - HIV drugs in Sweden

Dr L inda Morfe ld t , Karol inska Hospi ta l , Sweden

Mr Anders Sundström, Medical Products Agency, Sweden

Round Table discussion on key issues relat ing to topics from

the WHO meeting

Proposals for co-operation betweenWHO and ISoP for the

benefi t of world-wide drug safety and public health

Prof Vladimir Lepakhin

Closing Session of the 27th WHO Annual Meeting of National

Centres

Welcome Reception - Chester Beatty Library, Dublin Cast le

Meeting of the ISoP Executive Committee

10

T H U R S D A Y , 7 T H O C T O B E R

P L E N A R Y H A L L

SE S S I O N SP E A K E R S TI T L E

09.00-09.20 OP E N I N G SE S S I O N ISOP AN N U A L ME E T I N G (PL E N A RY HA L L)Mr. Pat O’Mahony, Chie f Execut ive Of f icer, IMB

Ms. Niamh Arthur, Phar macovigi lance Co-ordinator, IMBPr of . Giampaolo Ve lo , Uni Ver ona, Pr es ident o f ISoP

09.20-11.00

Chair :

Co-Chair

1. Medication errors

Prof. Ralph Edwards

Dr Thierry Trenque

11.20–13.00 2. Pharmacovigilance Planning

Chair : Dr. Abida Haq

Co-Chair : Dr. Priya Bahri

09:20-09:30

09:30-09:45

09:45 -10:00

10:00-10:15

10:15-10:30

10:30-10:45

10:45-11:00

R Edwards

R Edwards

P Caduff-Janosa

I Nnani

R Leone

D Chi

S Agarwal

Chairman’s introductory overview

WHO world alliance for patient safety

Medication errors in Switzerland: an analysis ofthe spontaneous adverse reaction reports receivedat the swissmedic pharmacovigilance centre

Counterfeit medicine; medication errorprone

Errors in drug therapy transmission fromdoctors to nurses: an hospital pilot study

Clinical pharmacist's role inpharmacovigilence in a cardiovascular wardof China

Medication errors in India

11:20-11:35

11:35-11:50

11:50 -12:05

12:05-12:20

12:20-12:30

12:30-13:00

X Kurz

C Martinez

S Shakir

P Bahri

A Haq

The ICH pharmacovigilance planning guidance

The General Practice Research Database-animportant resource for pharmacovigilance planning

The evidence base for drug withdrawals

An EMEA perspective on pharmacovigilance plans

Use of pharmacovigilance plans in non-ICHcountries

Discussion

14.20–16.00 3. Vaccine Vigi lance

Chair : Dr. Elisabeth Loupi

Co-Chair : Prof. Chalbi Belkahia

14:20-14:30

14:30-14:45

14:45-15:00

15:00 -15:15

15:15-15:35

15:35-16:00

E Loupi

K Hartmann

K Iskander

A Dodoo

U Mehta

K Connolly

Chairperson’s introductory overview

From signal detection to hypothesis testing ; facialparesis following intranasal flu immunisation

Increasing complexity of vaccine safety surveillancedatabases: the case for 'data mining

Safety monitoring of a new pentavalent vaccine inGhana’s Expanded Programme on Immunization (EPI)

Global overview of vaccine safety monitoring: progress,challenges and opportunities

Prediction of adverse events following immunisation(AEFI)

16 .20–18 .00 4. Depression and suicide as ADRs

Chair : Dr. David Coulter

Co-Chair Dr John F Connolly

16:20-16:40

16:40-17:00

17:00 -17:20

17:20-17:35

17:35-17:50

17:50-18:00

D Coulter

J F Connolly

I R Edwards

B Caffari

K. Kamagate

Depression and suicide as ADRs – an introduction

A psychiatrist’s view of depression and suicide asADRs

Data mining insights on SSRIs & suicide

SSRI adverse events in the italian population

Intoxication by medicinal plants in Abidjan: clinicaland ethnobotanical aspects

Discussion

11.00-11.20 CO F F E E BR E A K (Posters Displayed for Review)

13.00 – 14.20 LU N C H A N D PR E S E N TAT I O N/RE V I E W O F TH U R S D AY PO S T E R S

16.00–16.20 CO F F E E BR E A K (PO S T E R S D I S P L AY E D F O R R E V I E W)

19.00–22.30 OF F I C I A L CO N F E R E N C E DI N N E R

11

T H U R S D A Y , 7 T H O C T O B E R

SY N D I C AT E RO O M S 1S T FL O O R ~ “DO D D E R/DA R G L E”

SE S S I O N SP E A K E R S TI T L E

09.20-11.00

Chair :

Co-Chair

A. Safety of new drugs used inmetabolic disorders in the elderly

Dr Kenneth Hartigan-go,

Prof Brian Sheppard

11.20–13.00 B. Benefit/risk of OTC analgesics

Chair : Prof Nicholas Moore

Co-Chair : Prof Jörg Hasford

09:20-09:40

09:40-10:00

10:00 -10:20

10:20-10:40

10:40-11:00

K Hartigan-go

D Coppola

L Wilton

H Berthold

L Wilton

Chairman’s introductory overview

Glimepiride and glibenclamide: summary of toxicepidermal necrolysis and Stevens Johnson Syndrome

The management and outcomes of specific adverse drugreactions in patients prescribed pioglitazone in primarycare in England; interim results

“Phossy jaw” revisited – do bisphosphonates cause“bisphossy jaws”?

Ophthalmological events in patients taking risedronate:follow up information in a prescription-event monitoringstudy

11:20-11:40

11:40-11:55

11:55 -12:10

12:10-12:25

12:25-12:40

12:40-13:00

N Moore

A Bijl

M Voelker

L Bensouda

MOllagnier

J Hasford

Chairman’s introductory overview

Anaphylactic reactions to over the counter (OTC)analgesics, particularly propyphenazone-combinations

Safety and tolerability of aspirin in randomisedcontrolled clinical trials

Is the risk of upper gastrointestinal bleedingincreased with NSAIDs used as analgesics, inchildren : a case crossover study.

Aryl carboxylic non-steroidal inflammatory drug (AC)induced serious renal adverse effects result of afrench national survey

Safety and appropriateness of use of a low-dose OTCNSAID: methodological issues and results of apharmacy-based cohort study

14 .20–16 .00 C.Training & Communication in Pharmacovigilance

Chair : Prof Giampaolo Velo

Co-Chair : Dr Paula Marquez

14:20-14:35

14:35-14:55

14:55-15:10

15:10-15:25

15:25-15:45

15:45-16:00

G Velo

S Olsson

G PPolimeni

C Anton

P Marquez

Issues relating to drugs, the media and communication

Ten years of international pharmacovigilance trainingby the Uppsala Monitoring Centre

www.ecm.farmacovigilanza.org: an Italian website forCME in pharmacovigilance

Does informing GPs about common adverse drugreactions (ADRs) influence ADR reporting rates?

The next steps in the ISoP education & Training Project

Discussion

16 .20–18 .00 D. Surrogate Markers in Pharmacovigilance

Chair : Dr Jürgen Beckmann

Co-Chair Dr Mary Teeling

16:20-16:40

16:40-17:00

17:00-17:20

17:20-17:40

17:40-17:55

17:55-18:00

M Teeling

R Shah

J Beckmann

B Sachs

L Wilton

Co-chairperson’s introductory overview

QT-prolongation

APC-resistance as a surrogate marker for drugthrombogenicity

The lymphocyte transformation test (LTT) as a surrogatemarker for drug sensitization

The management and outcomes of specific adverse drugreactions in patients prescribed rosiglitazone in primarycare in England

Discussion

11.00-11.20 CO F F E E BR E A K (Posters Displayed for Review)

13.00 – 14.20 LU N C H A N D PR E S E N TAT I O N/RE V I E W O F TH U R S D AY PO S T E R S

16.00–16.20 CO F F E E BR E A K (PO S T E R S D I S P L AY E D F O R R E V I E W)

19.00–22.30 OF F I C I A L CO N F E R E N C E DI N N E R

12

F R I D A Y , 8 T H O C T O B E R

P L E N A R Y H A L L

SE S S I O N SP E A K E R S TI T L E

11.00–12.40 6. Future challenges in pharmacovigilance

Chair : Prof. Ingemar Persson

Co-Chair : Prof. Paul McKeigue

14.00–14.20 Overview of Key Meeting IssuesDr. Jürgen Beckmann

14.20-14.50 Award of poster prizes and short scienti f ic presentat ions by the winners

14.50-15.40 11. Keynote address (Plenary Hall)“The impact of the National Institute for Clinical Excellence (NICE) on drug safety” Prof Sir Mike Rawlins, UK

15.40-16.30 General Assembly of ISoP

16.30-17.00 Invitat ion to the ISoP 2005 Annual Meeting in Manila , Phil ippines

Closing Session

Ms. Niamh Ar thur, Dr. Kenneth Har t igan-go, Prof . Giampaolo Velo

09.00-10.40 5. Enhancing ADR reporting

Chair : Dr. Ronald Meyboom

Co-Chair : Prof. Sandeep Agarwal

09:00-09:10

09:10-09:25

09:25-10:40

10:40-10:55

10:55-11:10

11:10-10:25

10:25-10:40

R Meyboom

L Borsellino

F Salvo

GDalmacion

M Ferreira-Herdeiro

G Polimeni

E VanPuijenbroek

Chairmans’ introductory overview

Organization of regional centres ofpharmacovigilance: the example of Sicily(Italy)

Signal detection in spontaneous reporting Database: data from GIF, an italian inter-regional database

Pharmacovigilance in Public Health programs:do we need it?

Physician reporting of adverse drug reactions:a case-control study in Portugal.

Feedback information to reporters as a toolfor continuing education in pharmacovigilance

Time required for follow up information onspontaneous reports

11:00-11:10

11:10-11:30

11:30-11:55

11:55 -12:15

12:15-12:35

12:35-12:40

I Persson

L Middleton

P McKeigue

E. JaquenoudSirot

R Edwards

Chairman’s introductory overview

Recent developments in pharmacogenetics andpotential applications in pharmacovigilance

EUDRAGENE and related projects

TDM and pharmacogenetic tests as tools inpharmacovigilance

Knowledge finding in IMS disease analyzerMediplus UK database – effective data mining inlongitudinal patient safety data

Discussion

10.40-11.00 CO F F E E BR E A K (Posters Displayed for Review)

12.40 – 14.00 LU N C H A N D PR E S E N TAT I O N/RE V I E W O F FR I D AY PO S T E R S

13

F R I D A Y , 8 T H O C T O B E R

SY N D I C AT E RO O M S 1S T F L O O R - “DO D D E R/DA R G L E”

SE S S I O N SP E A K E R S TI T L E

11.00–12.40 F. Patient-related risk determinants (excl drug-druginteractions)

Chair : Prof. Rudolf Stoller

Co-Chair : Ms Sevgi Öksüz

09.00-10.40 E. Heparin-induced thrombocytopenia and other haematological ADRs

Chair : Prof Andreas Greinacher

Co-Chair : Prof. Saad Shakir

09:00-09:30

09:30-09:45

09:45 -10:00

10:00-10:15

10:15-10:25

10:25-10:40

A Greinacher

G Traversa

F. Haramburu

V Gras-Champel

V Gras-Champel

R Meyboom

Drug-induced immune thrombocytopenia withspecial focus on heparin-inducedthrombocytopenia

Thrombocytopenia associated with non-cytotoxic drug use: a prospective case-controlstudy

Drug-induced haemorrhage in communitypractice

Risk factors for bleeding in patients with oralanticoagulant treatment (OAT) andsupratherapeutic international normalised ratio(INR) when hospitalised

Can colchicine potentiate the anticoagulanteffect of fluindione ?

Reports of leukaemia and lymphoma duringthe use of clozapine and other atypicalneuroleptics

11:00-11:10

11:10-11:25

11:25 -11:40

11:40-11:55

11:55-12:10

12:10-12:25

12:25-12:40

R Stoller

A Zaïem

K Aouam

M Tuccori

M Smadja

A Conforti

Chairman’s introductory overview

Adverse drug reactions in elderly: results ofTunisian national centre of pharmacovigilance

Clinical findings of acetylsalicylic/ non-steroidalanti-inflammatory drugs-induced urticaria

Haemorrhagic gastritis and severe bleedingfollowing rofecoxib administration: a case report

Is weekly-administration of paclitaxel less toxicthan 3-weekly? A prospective pharmacovigilancestudy based on patient’s and physician’s reports.

Ciclosporin and serious intestinal disorders

Discussion

10.40-11.00 CO F F E E BR E A K (Posters Displayed for Review)

12.40 – 14.00 LU N C H A N D PR E S E N TAT I O N/RE V I E W O F FR I D AY PO S T E R S

I S O P P O S T E R P R I Z E

Prizes will be awarded for the three best posters at the ISoP Annual Meeting. All posters accepted for the Annual Meeting are eligible for a prize.

Posters will be displayed in the Alexandra Room on the ground floor on Thursday 7thOctober and Friday 8th October 2004 between 09:00 and close of the meeting each day.

Presenters are asked to put up their poster between 08:00 and 09:00 on the appropriate dayand staff will be available in the Alexandra Room to help during this time.

Presenters are also asked to be in attendance of their posters between 12.30 and 14:00 onthe relevant day.

Thursday 7th October 2004

05, 20, 25, 30, 55, 60, 70, 80, 85, 95, 100, 110, 117, 125, 135, 150, 185, 205, 215, 220, 225,

230, 260, 275, 285, 305, 310, 315, 360, 365, 370, 375, 380, 385, 420, 425, 410, 430, 440, 460,

475, 476, 477, 485, 505, 515, 520, 570, 580, 585, 615, 635, 645, 650, 665, 670, 690, 700, 705,

710, 715, 725, 750

Friday 8th October 200415, 40, 105, 120, 190, 195, 235, 240, 250, 255, 290, 300, 325, 330, 340, 345, 350, 390, 395,400, 405, 445, 465, 470, 510, 540, 555, 560, 565, 595, 620, 625, 640, 655, 675, 680, 685, 695,º720, 755

14

P005 HYPERTENSION INDUCED BY CYCLOSPORIN IN RENAL TRANSPLANTM.A. Ait El Cadi, Y. Khabbal, M. Aghrouch, S. Soussi Tanani, N.O. Ouzeddoun, Y. Cherrah

P015 HOW TO INCREASE THE SPONTANEOUS REPORTING IN ARGENTINA?L. Alesso, R. Herrera, C. Saidman, P. Lipszyc,R. Iannantuono

P020 LACK OF EFFICACY IN ANAESTHETICSL. Alesso, R. Herrera, V. Costamagna, G. Campos

P025 MEDICATION ERRORS IN ANAESTHESIAEL. Alesso, E. Casini, E. Gallino, P. Lipszyc, C. Chiale,M. Limeres, C. Saidman

P030 PHARMACODYNAMIC AND PHARMACOKINETICINSIGHTS IN HEADACHE PATIENTS WITH DRUG OVERUSEB. Alfredo, A. Capasso, S. Salomone

P040 ANALYSIS OF ADR REPORTS FOR YEAR 2003P.S. Ang, B.H. Tan, K.N. Ting, Ch.L. Chan

P55 AGREEMENT OF EXPERT JUDGMENT IN ASSESSMENT OF CAUSALITY OF ADVERSE DRUG REACTIONSY.A. Arimone, B.B. Bégaud, G.M. Miremont-Salamé,F.H. Haramburu, A.F. Fourrier-Réglat

P60 INTER-EXPERT AGREEMENT ABOUT SEVEN OPERATIONAL CRITERIA FOR CAUSALITY ASSESSMENT OF ADVERSE DRUG REACTIONSY.A. Arimone, B.B. Bégaud, A.F. Fourrier-Réglat,F.H. Haramburu, G.M. Miremont-Salamé

P70 SPONTANEOUS REPORTING OF ADRS ASSOCIATEDWITH HERBAL MEDICINES: A CROSS-SECTIONAL SURVEY OF NATIONAL PHARMACOVIGILANCE CENTRES J. Barnes, A. Aggarwal

P80 A RARE DRUG REACTION TO METHOTREXATE AFTER TREATMENT FOR ECTOPIC PREGNANCY.Y. Benjelloun

P85 DRUG USE DURING PREGNANCY AND LACTATIONY. Benjelloun, F. Benzekri, A. Ansari, M. Taibi Ouazzani

P95 ALLERGIC VASCULITIS TO BETA LACTAMINSR. Benkirane, M. SBIHI, L. Alj, M.A. Sbihi,R. Soulaymani, Y. Khabbal

P100 DRUG INDUCED CUTANEOUS REACTIONS : RETROSPECTIVE ANALYSIS OF THE CASE REPORTSR. Benkiran, M. SBIHI, L. Alj, M.A. Sbihi, R. Soulaymani

P105 HEMOCHOLECYSTIS RESULTING FROM INTERACTION BETWEEN ANTICOAGULANT ANTIVITK AND CELECOXIBR. Benkirane, M. SBIHI, L. Alj, M.A. Sbihi, R. Soulaymani

P110 PROLONGED ARTERIAL HYPOTENSION FOLLOWING PROPOFOL INDUCTIONR. Benkirane, M. SBIHI, L. Al, M.A. Sbihi, Y. Khabbal,R. Soulaymani

P117 SEROTONIN SYNDROME INDUCED BY MIRTAZAPINE MONOTHERAPYrb Bertoli, M Tosi, G Vanini, P Caduff, A Cerny

P120 SERIOUS SIDE-EFFECTS OF BUPROPION. WHO IS AT RISK AMONG 524 000 EXPOSED PATIENTS?M.N. Beyens, S. Laporte, M. Ollagnier

15

P125 COPRESCRIPTION OF GASTROPROTECTIVE AGENTS AND SHIFTING BETWEEN DRUGS: IS THERE A DIFFERENCE BETWEEN TRADITIONAL NSAIDS AND COXIBS?C. Bianchi, I. Abraha, C. Romagnoli, G. Traversa

P135 ANALGESICS AND HEPATO-BILIARY INJURIES : A PHARMACOEPIDEMIOLOGICAL CASE/NON CASE STUDY.A. Bonneau, C. Remblier, M.C. Perault

P150 AGE AND GENDER DISTRIBUTION OF CUTANEOUS DRUG REACTIONS IN FRANCEH.B. Brocvielle, J.C.R. Roujeau, L.T. Thomas,H.L.L. Le Louet

P185 MESSAGE FROM THE TOP: CHIEF PHARMACISTS VIEWS OF ADVERSE DRUG REACTIONS REPORTING.A.R. Cox, J.F. Marriott, K.A. Wilson, R.E. Ferner

P190 PILOT PROGRAM ACTIVITY COSMETIC-VIGILANCE COSMETIC-SURVEILLANCE ACTIVITY: INQUIRY ABOUT COSMETICS ADVERSE REACTIONS BETWEEN QUESTIONNAIRE IN FIVE PHARMACIES OF NAPLES.C.D.G. Di Giovanni Carmen, L.S. Lidia Sautebin,V.A. Vincenzo Arcoraci, L.G. Loredana

P195 DRUGS AND DEAFNESS: A PHARMACOEPIDEMIOLOGICAL CASE/ NON CASE STUDYE. Divoux, C. Remblier, M.C. Perault

P205 ADVERSE EFFECTS IN HIV INFECTED PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS (HCV) RECEIVING ANTIRETROVIRAL TREATMENT AND THE TREATMENT OF TUBERCULOSIS INFECTIONJ. Dragovic, L.J. Djordje Jevtovic

P215 LIVER TOXICITY OF LOPINAVIR/RITONAVIR-CONTAINING REGIMENS IN HIV-INFECTED PATIENTS WITH OR WITHOUT HEPATITIS C VIRUS (HCV) CO-INFECTIONJ. Dragovic, L.J. Djordje Jevtovic

P220 LOPINAVIR/RITONAVIR VS. INDINAVIR/RITONAVIRIN HIV INFECTED PATIENTS: IMMUNO-VIROLOGICAL OUTCOME AND SIDE EFFECTSJ. Dragovic, L.J. Djordje Jevtovic

P225 LOW DOSE STAVUDINE: AS EFFECTIVE AS STANDARD DOSE BUT LESS SIDE EFFECTSJ. Dragovic, L.J. Djordje Jevtovic

P230 HOIGNE SYNDROME: CASE REPORTS AND MECHANISM OF PATHOGENESISS. El Aïdli, A. Zaïem, R. Daghfous, S. Sraïri, A. Klouz,M. Lakhal, M.H. Loueslati, C. Belkahia

P235 FAILURE OF ORAL CONTRACEPTIVES DURING THE USE OF HYPERICUM-CONTAINING DRUGSJ. Ericsson, R. Savage, M. Farah, R.H.B. Meyboom

P240 PHARMACIST’S ATTITUDES AND BEHAVIOUR RELATED TO REPORTING ADVERSE DRUG REACTION. A CASE-CONTROL STUDY IN PORTUGAL. M.T.F.H.Ferreira Herdeiro, F.A. Figueiras, P.M.M. Pinto, P.J.J. Polónia

P250 PATIENT EXPERIENCE REPORTS CAN HELP IMPROVE THE QUALITY OF EPILEPSY TREATMENTE.H. Fietjé, A.C.G. Egberts, T. Tempels, R.H.B. Meyboom

P255 NEUROPSYCHIATRIC ADVERSE DRUG REACTIONS IN GENERAL PRACTICEL. Galatti, S.E. Giustini, A. Sessa, G. Polimeni, F. Salvo,E. Spina, A.P. Caputi

P260 CASE REVIEW OF COX-2 SPECIFIC INHIBITORS RELATED ADRS RETRIEVED ROM THE DATABASE OF THE NATIONAL ADVERSE DRUGS REACTION REPORTING SYSTEM IN TAIWANC.S. Gau, Y.T.Y. You

P275 SURVEY ON TEENAGERS' SELF-MEDICATIONV. Gras-Champel, A.S. Lemaire-Hurtel, S. Lefevre-Skil,H. Masson, M. Andréjak

P285 MISUSE OF EMERGENCY CONTRACEPTION PILL?F. Haramburu, M.L. Laroche, C. Metge,G. Miremont-Salamé, B. Bégaud, F. Haramburu

P290 USE OF COMPLEMENTARY OR ALTERNATIVE PRODUCTS IN CANCER PATIENTSF. Haramburu, E. Apretna, C. Baillot-Hadjaj,G. Miremont-Salamé, C. Donamaria, M. Pommier,B. Hoerni, N.D. Moore, B. Bégaud, F. Haramburu

P300 ADVERSE UNEXPECTED EFFECT: IMPROVEMENT OF A PSORIASIS WITH BUPROPIONS. Havet, J.Y. Schlienger, A. Molia, M.L. Germain,T. Trenque

P305 FACTITIOUS HYPOGLYCAEMIA ASSOCIATED WITHSULPHONYLUREA DRUGS IN FRANCE DURING THREE YEARS.S. Havet, G. Hoizet, A. Molia, M.L. Germain, T. Trenque

P310 ADVANCES OF ADR REPORTING SYSTEM IN TAIWAN AND CASE REVIEW OF ANTIDEPRESSANTS FROM ADR DATABASEY.W. Huang, C.S. Gau, C.W. Hsu, H.C. Yen, H.P. Wang

P315 CENTRAL NERVOUS SYSTEM ADVERSE REACTION INDUCED BY CEFEPIME IN A FEMALE HEMODIALYSIS PATIENT - A CASE REPORTM. Huic, I. Francetic, M. Mayer, J. Pasini, M. Bilusic,V. Macolic Sarinic, I. Bakran

P325 IMMUNE AGRANULOCYTOSIS AND CLARITHROMYCINP. Jacobs, A. Conforti, L. Wood, A.K. Kiuru,G.O. Jones, D. Woolf

16

P330 FOLLOW-UP STUDY USING TDM AND PHARMACOGENETIC TESTING AS TOOLS IN PHARMACOVIGILANCEE. Jaquenoud Siro, C.B. Eap, P. Baumann

P340 VIGIMED, AN INTERNATIONAL DRUG SAFETY E-MAIL DISCUSSION GROUPK. Johansson, R.H.B. Meyboom, B. Hellman, S. Olsson

P345 COOPERATION BETWEEN THE NATIONAL PHARMACOVIGILANCE CENTRE AND REGISCAR IN THE NETHERLANDS: MUTUAL PROFITABLEJ.S. Kabel, E.P. Puijenbroek, J.N. Bouwes Bavinck

P350 CLINICAL TRIALS OF MEDICINAL PLANTS: BIBLIOGRAPHICAL REVIEW (1980-2000) AND METHODOLOGIC ANALYZESK. Kamagate, H. Die-Kacou, E. Balayssac,J.C. Yavo P.T. Daubret, K.A. Kakou, V.M. Gboignon

P360 SAFETY PROFILE OF PIOGLITAZONE AS USED IN GENERAL PRACTICE IN ENGLAND: RESULTS OF A PRESCRIPTION-EVENT MONITORING STUDYR.K. Kasliwal, L. Wilton, S.A.W. Shakir

P365 SAFETY PROFILE OF ROSUVAST-ATIN AS USED IN GENERAL PRACTICE IN ENGLAND: INTERIM RESULTS OF A PRESCRIPTION-EVENT MONITORINGSTUDYR.K. Kasliwal, L. Wilton, S.A.W. Shakir

P370 GENERALIZED TONIC-CLONIC SEIZURES AND PROPOFOLS. Kastalli, S. El Aïdli, R. Daghfous, S. Trabelsi, S. Srairi, A. Klouz, M. Lakhal, M.H. Loueslati, C. Belkahia

P375 GINGIVAL HYPERPLASIA INDUCED BY CYCLOSPORINE IN RENAL TRANSPLANTY. Khabbal, D. Soussi Tanani, M. Ait El Cadi,M. Aghrouch, N.O. Ouzeddoun, Y. Cherrah

P380 ADVERSE DRUG EVENTS AND POTENTIALLY INAPPROPRIATE MEDICATION USE IN THE ELDERLYM.L. Laroche, Y. Nouaille, J.P. Chaemes, T. Dantoine,L. Merle

P385 ARE GENERICS AS SAFE AS THEIR PRINCEPS COUNTERPARTS ?M.L. Laroche, Y. Nouaille, L. Merle

P390 INCIDENCE RATES OF CEREBROVASCULAR ACCIDENTS AND TRANSIENT ISCHAEMIC ATTACKS WITH ANTIPSYCHOTIC DRUGS IN GENERAL PRACTICE IN ENGLAND: A RETROSPECTIVE ANALYSIS OF PRESCRIPTION-EVENT MONITORING (PEM) DATA.D. Layton, S. Harris, L.V. Wilton, S.A.W. Shakir

P395 SAFETY PROFILE OF DESLORATADINE AS USED IN GENERAL PRACTICE IN ENGLAND: RESULTS OF A PRESCRIPTION-EVENT MONITORING STUDY.D. Layton, L.V. Wilton, S.A.W. Shakir

P400 SAFETY PROFILE OF LEVOCETIRIZINE AS USED IN GENERAL PRACTICE IN ENGLAND: RESULTS OF A PRESCRIPTION-EVENT MONITORING STUDY.D. Layton, A. McMillan, L.V. Wilton, S.A.W. Shakir

P405 IS THE DHE - TRIPTANS CONTRAINDICATION STILL JUSTIFIED?H.L. Lelouet, H. Allain, L. Guesnier

P410 DOMESTIC SELF-MEDICATION: AN ITALIAN ATTITUDINAL SURVEYR. Leone, I. Meneghelli, T. Camerlengo, S. Segat,U. Moretti, G.P. Velo

P420 ASSESSMENT OF PROLONGED-RELEASE TRAMADOL EFFICACY AND SAFETY IN GENERAL MEDICAL PRACTICE: A PROSPECTIVE OBSERVATIONAL STUDY.P. Lora Aprile, G. Trifiro, G. Mazzaglia, E. Sessa,O. Brignoli, A.P. Caputi

P425 APOMORPHINE GENERALLY WELL TOLERATED IN THE TREATMENT OF ERECTILE DYSFUNCTION: RESULTS OF A PRESCRIPTION-EVENT MONITORING (PEM) STUDY.K.M. Maclennan, K.M. Maclennan, A. Boshier,L.V. Wilton, S.A.W. Shakir

P430 SAFETY PROFILE OF REPAGLINIDE AS USED IN GENERAL PRACTICE IN ENGLAND: RESULTS OF A PRESCRIPTION-EVENT MONITORING STUDYV. Marshall, L.V. Wilton, S.A.W. Shakir

P440 TRAINING INITIATIVES IN VACCINE SAFETY MONITORING THROUGH THE WORLD HEALTH ORGANIZATION (WHO) GLOBAL TRAINING NETWORK (GTN)U. Mehta, A. Bentsi-Enchill, D. Lei, P. Duclos,L. Belgharbi, M. Zaffran, C. Belkahia, S. Peiris,T. Bektimirov, P.I. Folb

P445 ADVERSE EVENTS TO HERBAL PREPARATIONS: ALLERGIC REACTIONS TO PROPOLIS.FMI Menniti-Ippolito, F Menniti-Ippolito, G Mazzanti,F Firenzuoli, A Bianchi, C Santuccio, R Raschetti

P460 ACHIEVING EXCELLENCE IN AVENTIS UK PHARMACOVIGILANCEN. Mihajlovic- Gojkovic, J. Savage, M. Norwood,E. Mundy, A. McPherson, G. Braga, R. Richardson, P. Kon

17

P465 ADVERSE EVENTS ASSOCIATED WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART): A SURVEY IN HIV-INFECTED POPULATION OVER18-MONTH PERIODA. Molia, C. Strady, S. Havet, I. Beguinot, C. Rouger,J.L. Berger, A. Waldner, M.L. Germain, T. Trenque

P470 AGRANULOCYTOSIS DURING TREATMENT WITH CYAMEMAZINE AND VENLAFAXINEA. Molia, A.M. Blaise, B. Kolb, S. Havet, M.L. Germain,T. Trenque

P475 PHARMACOVIGILANCE PLANS FOR EMERGING ONCOLOGY COMPOUNDSS.R. Morgan, A.J. Hudson, H.D.J. Snow

P476 CHOLESTATIC HEPATITIS WITH FLUCLOXACILLIN: UK SPONTANEOUS REPORTS 12 YEARS ONJ N S Moseley, S Wark, J Woolley

P477 PRELIMINARY COMPARISON OF 2 SIGNAL DETECTION METHODOLOGIES IN THE UK REGULATORY AUTHORITY SPONTANEOUS ADR DATABASEJ N S Moseley, E Heeley, S Ekins-Daukes, S Evans

P485 VACCINE ASSOCIATED ADVERSE EVENT SURVEILLANCE (VAAES) AND QUALITY ASSURANCE (QA)

J.N. Nkanza, W. Walop

P505 REPORTS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FROM A PRESCRIPTION EVENT MONITORING STUDY OF YASMIN® IN ENGLANDH.M. Pearce, D. Layton, L.V. Wilton, S.A.W. Shakir

P510 SAFETY PROFILE OF SIBUTRAMINE AS USED IN GENERAL PRACTICE IN ENGLAND: RESULTS OF A PRESCRIPTION-EVENT MONITORING STUDYH.M. Pearce, L.V. Wilton, S.A.W. Shakir

P515 NEUROPSYCHIATRIC DISORDERS INDUCED BY ISOTRETINOIN. ANALYSIS OF CASES REPORTED IN THE FRENCH PHARMACOVIGILANCE DATABASE AND REVIEW OF THE LITERATUREP. Peyrière, P. Recolin, M.A. Thompson, J.P. Blayac,D. Hillaire-Buys

P520 SSRI-INDUCED HEPATOXICITY: REVIEW OF DATA FROM THE FRENCH PHARMACOVIGILANCE DATABASE AND LITERATURE.V. Pinzani, D. Hillaire-Buys, M. Creus-Findeling,M.L. Hemery, G. Pageaux, D. Larrey, J.P. Blayac

P540 CLINICO-TOXICOLOGICAL ASSESSMENT OF ATYPICAL ANTIPSYCHOTICSD. Prasa, G. Hüller, H. Hentschel

P555 A CASE REPORT OF RHABDOMYOLYSIS WITH PENTAMIDINE: SIGNAL REPLICATION UTILIZING A NEW PHARMACOVIGILANCE TOOL UNDER INVESTIGATION.L. Reich, M. Hauben

P560 POSTMARKETING SURVEILLANCE OF POTENTIALLY FATAL REACTIONS TO ONCOLOGY DRUGS: FINDINGS FROM TWO DATA MINING ALGORITHMS.L. Reich, M. Hauben, S. Chung

P565 USE OF A NEW PHARMACOVIGILANCE TOOL UNDER INVESTIGATION TO EVALUATE AN UNEXPECTED STRUCTURE-ADVESE EFFECT RELATIONSHIP INITIALLY IDENTIFIED BY LABORATORY RESEARCHL. Reich, M. Hauben

P570 AUTISM AND PEDIATRIC VACCINESA.R.V. - Roque Valdés

P580 FLUOROQUINOLONE (FQ)-ASSOCIATED ANAPHYLAXIS IN SPONTANEOUS ADR REPORTS: OCCURRENCE AFTER FIRST USE AND APPARENT DIFFERENCES IN REPORTING RATES BETWEEN FQSB. Sachs, S. Erdmann, S. Riegel, D. Schichler, H. Merk,J. Beckmann, A. Barger

P585 PRESCRIPTION ERRORS IN PRIMARY CARE: TYPES, DETERMINANTS AND THERAPEUTIC IMPLICATIONSR.P. Sequeira, T.M. Alansari, K.A. Alkhaja

P595 DEVELOPMENT OF PLANTS TOXICOLOGY TWO DATABASESS. Skalli, R. Benkirane, R. Soulaymani

P615 PHARMACOVIGILANCE OF CHILDHOOD VACCINATION IN ITALY, 2001-2003.S. Spila Alegiani, L. Pastore Celentano, C. Santuccio,B. Caffari, R. Raschetti, S. Salmaso, G. Traversa,M.L. Ciofi degli Atti

P620 HYPERSENSITIVITY TO GLUCOCORTICOIDS.S. Sraïri, S. El AÏdli, R. Daghfous, A. Klouz, S. Kastalli,A. Zaïem, M. Lakhal, M.H. Loueslati, C. Belkahia

P625 WHO SIGNALS FROM 1998 TO 2001 - A FOLLOW-UPK. Star, M. Ståhl, J. Strandell, M. Pettersson, M. Lindquist

P635 AGRANULOCYTOSIS ASSOCIATED TO CARBIMAZOLE : A CASE REPORTA. Tebaa, D. Soussi-Tanani, Y. Khabbal, N. Smires,S. Serragui, R. Soulaymani

P640 COMPLEMENTARY MEDICINES: CASE REPORTS OF ADVERSE REACTIONS DUE TO ADULTERATIONK.N. Ting, P.S. Ang, B.H. Tan, M.Y. Low,B.C. Bloodworth, C.L. Chan

18

P645 DRUGS INDUCED BULLOUS TOXIDERMIA NOTIFIED TO THE TUNISAN PHARMACOVIGILANCE CENTRES. Trabelsi, S. El Aïdli, S. Kastalli, R. Daghfous, M. Lakhal,M.H. Loueslati, C. Belkahia

P650 NEUROLOGICAL DISORDERS ASSOCIATED WITH VACCINE USE: A PROSPECTIVE CASE-CONTROL STUDYG. Traversa, A. Capuano, R. Da Cas, F. Menniti-Ippolito, R. Rossi, S. Renna, P. Barabino, N. Pirozzi, C. Cecchetti, V. Iori, U. Raucci, G. Viviano

P655 ADVERSE DRUG EVENTS IN EMERGENCY DEPARTMENT POPULATION: A PROSPECTIVEITALIAN STUDYG. Trifiro, G. Calogero, F. Menniti Ippolito,M. Cosentino, R. Giuliani, A. Conforti, M. Venegoni,G. Mazzaglia, A.P. Caputi

P665 POSTMARKETING SURVEILLANCE OF RISEDRONATE IN FILIPINO PATIENTS WITH OSTEOPOROSISC.I. Valencia, J.N. Sarol, J.R. Dimaano, N.C. Cruz, Actonel Study Group

P670 NON STEROIDAL ANTI-INFLAMMATORY AGENT AND EDEMA : RESPONSIBLE OF HOSPITALIZATIONIN 50% OF CASES.V.R. Valnet Rabier, C. Legalery, J.P. Kantelip

P675 CHALLENGES FOR A JAPANESE COMPANY IN EUROPEJ.W. van der Velden

P680 THE DRUG SAFETY UNIT IN A CROJ.W. van der Velden

P685 LOW MOLECULAR WEIGHT HEPARINS. REPORTING RATE INCIDENCE AND PROFILE OF ADVERSE REACTIONS REPORT IN SPAIN.E. Vera, V. García del Pozo, J. García del Pozo,L.H. Martín Arias, A. Velasco, A. Carvajal

P690 SUICIDAL ATTEMPTS IN YELLOW CARDS REPORT ON THE SPANISH PHARMACOVIGILANCE SYSTEME. Vera, V. García del Pozo, J. García del Pozo,L.H. Martín Arias, A. Velasco A. Carvajal

P695 DRUG-INDUCED HYPONATREMIAS (DIH): A 5-YEAR SURVEY OF THE FRENCH PHARMACOVIGILANCE DATABASET. Vial, A. Roudon, P. Auriche, N. Bernard, C. Payen,J. Descotes

P700 MEDICATION ERRORS: EXPERIENCE OF A POISON CENTERT. Vial, C. Pulce, C. Boluda-Garayt, S. Merindol,C. Bavuz, C. Payen, P. Frantz, J. Descotes

P705 SEVERE TOXICITY ASSOCIATED WITH A DRUG CONTAINING DIETHYLENE GLYCOL ETHYL-ETHER(DEGEE) AS AN EXCIPIENT: REPORT OF 6 CASEST. Vial, P. Harry, H. Eftekhari, H. Jantzem,A.P. Jonville-Bera, B. Mosquet, C. Payen, J. Descotes

P710 THE IMPORTANCE OF REPORTING MEDICATION ERRORS WITH VACCINESW. Walop

P715 ELUCIDATING THE MECHANISM OF LITHIUM ACQUIRED NEPHROGENIC DIABETES INSIPIDUSI. Wilting, R. Baumgarten, K.L.L. Movig,J.H.M. van Laarhoven, A.J. Apperloo, W.A. Nolen,E.R. Heerdink, A.C.G Egberts

P720 A COHORT STUDY TO MONITOR THE MANAGEMENT AND OUTCOMES OF SELECTED ADVERSE DRUG REACTIONS WITH CARVEDILOL WHEN USED FOR CARDIAC FAILURE IN ENGLANDL.V. Wilton, B. Aurich Barrera, V. Marshall, S.A.W. Shakir

P725 SAFETY PROFILE OF TIOTROPIUM USED IN GENERAL PRACTICE IN ENGLAND: INTERIM RESULTS OF A PRESCRIPTION-EVENT MONITORING STUDYL.V. Wilton, S.A.W. Shakir

P750 TITLE: THE IMPACT OF RISK COMMUNICATION STRATEGIES ON NEFAZODONE PRESCRIPTION TRENDS IN CANADA BETWEEN 1994 AND 2003J. Zhang, V. Hogan, D. Clapin

P755 DRUG SURVEILLANCE AND INFORMATION CENTER: EFFICACY ON ALERT SIGNAL DETECTIONM. del Zompo, M.E. Stochino, R. de Lisa, C. Asuni,G. Severino, C. Chillotti, R. Ardau

S O C I A L P R O G R A M M E

The Local Organising Committee would like to acknowledge the contribution ofAstraZeneca and Janssen-Cilag towards the welcome reception.

W E L C O M E R E C E P T I O N ( W E D 6 T H O C T O B E R 2 0 0 4 )

18.30 - 20.30

The Welcome Reception will take place in the Atrium of the Chester Beatty Library, situated

in the Clock Tower Building of Dublin Castle. The Library was recently voted ‘European

Museum of the Year 2002’, the first occasion for Ireland. Tour guides will be available on

the night to answer any questions you may have on the collections. The library is situated

adjacent to Dublin Castle on the map below.

The Chester Beatty library is approximately a 20-25 min walk from the Conference Venue,

or is a short trip in a taxi.

Bus transportation will be arranged from the meeting venue to the welcome reception.

C O N F E R E N C E D I N N E R ( T H U R S 7 T H O C T O B E R 2 0 0 4 )

19.00 - 22.30

The official Conference Dinner will take place in the Old Jameson Distillery in Dublin’s

historic Smithfield. Originally built in 1780, the whiskey Distillery has been recreated to its

former world-renowned glory and is now an award-winning visitor attraction. A guided tour

will be provided on the night and guests will be treated to the lively ‘Shindig’ including

musicians, a five-course meal and optional whiskey tasting.

Bus transportation will be arranged from the meeting venue to the conference dinner.

Please note that smoking is not permitted in either of these venues at any time.

Please see map on page (iii) for location of the above venues.

19

G E N E R A L I N F O R M A T I O N O N I R E L A N D

B A C K G R O U N D I N F O R M A T I O NClimate:

The weather in Ireland in October is generally mild (9-18oC) and usually pleasant, but may be

showery.

Dublin – Local Attractions:• Trinity College, 0.5 mile. S• National Concert Hall, 1 block S• National Art Gallery, 0.5 mile. S• Natural History Museum, 0.5 mile. S• St. Stephen's Green, 0.5 block S• Leinster House, 0.5 mil. S• Temple Bar, 1 km. N

Visit www.ireland.ie for more information

Money

The unit of currency used in Ireland is the euro (€). One euro consists of one hundred cent.

Notes are €5, €10, €20, €50, €100, €200 and €500. Coins are €2, €1, 50c, 20c, 10c, 5c, 2c and 1c.

Credit CardsAny credit cards that bear the Visa, MasterCard or American Express symbol will be widelyaccepted in Ireland. Visitors with other cards should ask in advance or see if that card is ondisplay where they wish to use it.

BanksOpening HoursMonday through Friday: 10.00 a.m. – 4.00 p.m. Thursday: 10.00 a.m. – 5.00 p.m.

ATM (cash) machines are located at most banks and accept most credit and debit cards.American Express: Opening HoursMonday – Saturday: 9.00 a.m. – 5.00 p.m.

Thomas Cook Ltd. Opening HoursMonday – Friday: 09.00 a.m. – 5.00 p.m.Saturday: 09.00 a.m. – 12.00

Post Office Opening HoursMonday – Friday 09.30 a.m. – 1.00 p.m. 2.15 p.m. – 5.30 p.m.

20

Electricity

The Irish electrical current is 220 volts. The most commonly used plugs are 3-pin flat. As

Irish voltage is different to US/Canadian voltage, you will need to bring/buy a voltage

converter if you are bringing electrical appliances. Voltage converters are available from

most electrical stores.

Emergency Services – Police, Fire, Ambulance:

Tel: 112 or 999.

These numbers are free of charge but should only be used in cases of genuine emergency.

On answer, state which service you require, wait to be connected to that service, then

clearly state the location of where the assistance is required.

In the case of a vehicle breakdown:

Automobile Association (AA)

Tel: 1800 66 77 88

RAC Motoring Service

Tel: 1800 535 005

Telecommunications

Pay Phones

Pre-paid phone cards are widely available and are both convenient and effective to use.

Telephone Enquiries

Directory Enquiries: 11811 (for any number you need within Ireland & Northern Ireland

11818 (for any number you need outside Ireland

Operator Assistance: 10 (Ireland, Northern Ireland & Britain)

114 (International)

Telephone Codes

If calling Republic of Ireland from abroad all telephone numbers must be prefixed with

00 353 (drop the first 0 of the local code)

International access code from Ireland is always 00 followed by country code, area code etc.

Smoking ban within the Republic of Ireland

Ireland introduced a blanket ban on smoking in all work places to protect public health

and reduce the incidences of smoking-related illness in March 2004.

No smoking is allowed in public areas – this includes all bars, nightclubs and restaurants.

Although hotel bedrooms will be exempt from the ban, it applies to all other areas within

hotels.

21

N O T E S

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

..........................................................................................................................................................................................

22